Germany: A Revolution of Reimbursement in Germany

Last Updated: 10 January 2011
Article by Christian Fulda

New legislation effective January 1, 2011, will revolutionize reimbursement for pharmaceuticals in Germany. Pharmaceutical and biotechnology companies currently developing products need to take a "fourth hurdle" into account, in addition to demonstrating quality, safety, and efficacy. They will also have to demonstrate an additional clinical benefit over the standard therapy. This will need to be taken into account when designing clinical trials during drug development.

From Free Market Access to Negotiated Market Access

From a business perspective, Germany was for a long time an attractive market for innovative pharmaceuticals (including biopharmaceuticals), as reimbursement by the public health system in general occurred at the prices set by the pharmaceutical companies. The legislator had introduced rebates in favor of the public health system, and increased them earlier this year to 16 percent, at the same time extending this rebate to pharmaceuticals distributed to patients in private health insurance plans. Nevertheless, the originators had been free to set the initial asking price, with the added advantage that this list price in Germany was referenced in reimbursement price calculations by a range of other European countries.

This is about to change as of January 1, 2011. On December 17, 2010, the act introducing this change passed the last legislative approval required. One day earlier, the German Federal Government had approved the implementing regulation. The law is entitled "Act on the reorganization of the pharmaceutical market in the public health insurance" (Gesetz zur Neuordnung des Arzneimittelmarktes in der gesetzlichen Krankenversicherung or Arzneimittelmarktneuordnungsgesetz, or "AMNOG"). In fact, the act fundamentally changes reimbursement in Germany, and thus can be described as a revolution rather than a reorganization. In the best case, reimbursement prices have to be negotiated. In the worst case, reimbursement is limited to that which is granted to comparable products.

The Procedure

The originator has to file documentation on the benefits of a product at the latest by the first time of placing a product on the German market. The same applies for new indications. For existing products, such documentation may be requested on a case-by-case basis. The documentation has to be filed with the Joint Federal Committee (Gemeinsamer Bundesausschuss, or "G-BA"), a body of the German public health system. It has to include, in particular, data on the additional medical benefit in relation to the "appropriate comparator therapy," on the number of patients and group of patients for which of a significant additional therapeutic benefit exists, and on the costs of the therapy for the public health system.

Within three months, the G-BA is required to assess the benefit of the product and to publish this assessment. The G-BA may carry out the assessment itself or may delegate it. The stakeholders both from the medical and the industry side shall be heard on the assessment in writing and/or in oral presentations, before the assessment is published. Within a further three months, the G-BA has to decide on the benefit assessment. In particular, the G-BA has to determine whether an additional benefit exists.

If the determination denies an additional benefit, the product is immediately included into a group of comparable pharmaceutical and therapeutic characteristics, for which maximum reimbursement prices have already been set. If there is no such group, because the product is a pharmaceutical novelty, the reimbursement price has to be negotiated, but it may not exceed the annual costs of the "appropriate comparator therapy." The originator may only request a new assessment one year after the publication of the negative determination.

If the determination acknowledges an additional benefit, the originator has to negotiate the reimbursement price with the Federal Head Association of the Public Health Insurances (Spitzenverband Bund der Krankenkassen or Spitzenverband Bund). The negotiations have to be concluded within six months of the publication of the determination. Technically, the result of the negotiations is a rebate for the public health care system on the list price.

If the negotiations fail, an arbitration body has to determine the reimbursement price within a further three months. The arbitration body is composed of an independent chairman, two independent co-arbitrators, and two arbitrators for each of the public health care system and the pharmaceutical industry. The arbitrators representing the industry shall be appointed by the German federal industry associations. The arbitration body shall take into account the actual prices applicable in other European countries. The price determined by the arbitration body applies one year after the first placing of the product on the market (possibly retroactively, if the decision of the arbitration body is issued thereafter).

The originator may file suit against the price determination; however, the action does not stay the determination pending the outcome of the suit.

The Additional Benefit

The benefit of a product is further defined in the implementing regulation as the "patient relevant therapeutic effect." This includes the improvement of health, the shortening of the time of an illness, the prolongation of survival, the reduction of side effects, or the improvement in quality of life. Economic benefits, in particular macroeconomic benefits (e.g., indirect costs like work stoppage, rehabilitation, or reduced requirement for home care), are not taken into account. The additional benefit is one that is quantitatively or qualitatively superior to that of an "appropriate comparator therapy."

To the extent the product is comparable pharmacologically and therapeutically to existing products, the additional benefit has to be demonstrated as therapeutic improvement over such existing products. If the product is not comparable pharmacologically and therapeutically to existing products, the "appropriate comparator therapy" has to be determined according to the standards of evidence-based medicine. In case of alternatives, the more cost-efficient therapy shall be used, preferably one for which a fixed limit of reimbursement exists. The "appropriate comparator therapy" has to be an appropriate therapy in accordance with generally accepted standards of medical science, preferably a therapy for which endpoint trials exist and that has been proved and tested in clinical practice.

The starting point of the additional benefit assessment are the trials submitted for regulatory approval. However, the G-BA may request further trials. If data on patient-relevant endpoints cannot exist at the time of the assessment (e.g., demonstrating additional benefit in patient survival), the G-BA may set a deadline by which such data has to be submitted. The data is classified according to the categories of evidence-based medicine.

The additional benefit is classified by the implementing regulation according to six categories, from great improvement of the benefit of a therapy, to a benefit lower than that of the "appropriate comparator therapy." The statute does not require such categories, but it is to be assumed that the categories—in case an additional benefit is determined—will affect the price negotiations and any eventual determination by the arbitration body.

Originators may seek advice from G-BA on the data required to demonstrate the benefit of a drug under development, including on the "appropriate comparator therapy," as early as prior to entering phase III of clinical trials. The German authorities responsible for approving the applications for marketing authorizations may participate in such advice. The advice shall be documented in writing. Participation by the European Medicines Agency, which is responsible for evaluating applications for central marketing authorizations, is not provided for under the statute.

Orphan Drugs

For drugs designated as orphan drugs under the European regulation 141/2000, the additional benefit is deemed to be demonstrated by the marketing authorization. This special provision reflects the requirement for orphan drugs to demonstrate additional benefit over existing therapies in order to obtain orphan drug designation in the first place.

However, once an orphan drug generates annual gross sales of €50 million or more at the cost of the German public health system, the G-BA may request current data on the additional benefit, which the originator has to provide within three months. The procedure outlined above is then also applicable to orphan drugs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Christian Fulda
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.